Prolactin: The Milk-Producing Peptide Hormone
Pituitary Peptide Hormones
300+ known biological actions
Prolactin is one of the most versatile peptide hormones in the human body. Originally identified for its role in milk production, it has since been linked to over 300 distinct biological functions across immunity, metabolism, reproduction, and behavior.
Freeman et al., Physiological Reviews, 2000
Freeman et al., Physiological Reviews, 2000
View as imageProlactin was named for its role in promoting lactation, discovered in 1928 when pituitary extracts stimulated milk production in rabbits. That name understates the hormone's reach. Prolactin acts on more than 300 separate biological processes, from immune regulation to fat metabolism to parental behavior (Freeman et al., Physiological Reviews, 2000).[1] It is produced not only by the pituitary gland but also by the immune system, the brain, the uterus, and the mammary gland itself. It is the only pituitary hormone held under constant inhibitory control by dopamine, a regulatory mechanism that, when disrupted, underlies the most common pituitary hormone disorder: hyperprolactinemia. This article covers prolactin's structure, the peptide pathways that regulate it, its functions beyond the breast, what happens when levels are abnormal, and where current research is heading.
Key Takeaways
- Prolactin is a 199-amino-acid, 23 kDa single-chain peptide hormone synthesized primarily by lactotroph cells in the anterior pituitary, which constitute 20-50% of anterior pituitary cells (Freeman et al., 2000).[1]
- Dopamine from the hypothalamic tuberoinfundibular pathway tonically suppresses prolactin secretion; removing this inhibition is the primary mechanism behind most causes of hyperprolactinemia.[1]
- Prolactin-releasing peptide (PrRP) was identified as an endogenous stimulator of prolactin release, but subsequent research revealed it also regulates food intake and energy balance in rodents (Takayanagi et al., 2008).[5]
- Growth hormone-releasing peptides (GHRP-2, hexarelin) stimulate prolactin secretion alongside GH release, demonstrating cross-talk between pituitary peptide pathways (Arvat et al., 1997).[3]
- A 2026 study found that a PrRP analog reduced body weight in animal models through sustained fatty acid oxidation, opening a potential metabolic therapeutic application for this prolactin-related peptide (Feetham et al., 2026).[11]
- Prolactin plays a role in female-selective migraine mechanisms, with hormonal fluctuations in prolactin contributing to sex differences in headache disorders (Singh et al., 2024).[9]
Structure and molecular biology
Prolactin is a single-chain polypeptide of 199 amino acids with a molecular weight of approximately 23 kilodaltons. It contains three intramolecular disulfide bonds that maintain its three-dimensional structure. The hormone belongs to the prolactin/growth hormone/placental lactogen family, a group of structurally related peptide hormones that share a conserved four-helix bundle protein fold.[1]
The human prolactin gene is located on chromosome 6 and spans approximately 10 kilobases. An upstream promoter (approximately 5.8 kb upstream of the pituitary promoter) drives extrapituitary prolactin expression in decidual cells, lymphocytes, and other non-pituitary tissues. This dual promoter system means the same protein can be independently regulated in different tissues.
Prolactin circulates in multiple molecular forms. The dominant form is the 23 kDa monomer. "Big prolactin" (approximately 50 kDa) consists of covalently linked dimers. "Big-big prolactin" or macroprolactin (over 100 kDa) is prolactin bound to immunoglobulin G. Macroprolactin is biologically inactive but immunoreactive, meaning it can cause falsely elevated readings on standard prolactin assays. This is clinically relevant: an estimated 10-25% of hyperprolactinemia cases are actually macroprolactinemia, requiring polyethylene glycol (PEG) precipitation testing to distinguish true elevation from assay artifact (Saleem et al., 2018).[2]
Additionally, prolactin can be cleaved into a 16 kDa fragment (16K prolactin) that has anti-angiogenic properties distinct from the full-length hormone. This fragment inhibits blood vessel formation and has been implicated in peripartum cardiomyopathy, a condition where the heart weakens around the time of delivery.
How prolactin secretion is regulated
Prolactin is unique among anterior pituitary hormones: it is the only one held under tonic inhibitory control. Dopamine, released from tuberoinfundibular dopaminergic (TIDA) neurons in the arcuate nucleus of the hypothalamus, continuously suppresses prolactin secretion by acting on D2 receptors on lactotroph cells. Block dopamine or damage the pituitary stalk (interrupting dopamine delivery), and prolactin levels rise.[1]
Stimulatory factors. Several peptides and hormones stimulate prolactin release:
- Thyrotropin-releasing hormone (TRH) is the best-characterized prolactin-releasing factor. It stimulates both TSH and prolactin from the anterior pituitary, which is why hypothyroidism (elevated TRH) can cause hyperprolactinemia.
- Prolactin-releasing peptide (PrRP) was identified by Hinuma et al. (1998) as an endogenous prolactin secretagogue. PrRP exists in two forms (PrRP20 and PrRP31) and acts through the GPR10 receptor. Li et al. (2024) resolved the molecular mechanism of how PrRP binds its receptor, revealing a unique binding pose that may inform future peptide drug design.[7]
- Vasoactive intestinal peptide (VIP) stimulates prolactin gene transcription and secretion, particularly during suckling.
- Opioid peptides modulate prolactin through multiple pathways. Kiem et al. (1987) demonstrated that opiate agonists induced diurnal variation in prolactin and ACTH release, with distinct patterns for mu and kappa receptor activation.[4] Jaworski et al. (1997) showed that beta-endorphin immunoneutralization blocked prolactin release during suckling without affecting the dopaminergic system, establishing opioid peptides as independent mediators of the suckling-prolactin reflex.[6]
Short-loop feedback. Prolactin regulates its own secretion by stimulating TIDA neurons to release more dopamine. When prolactin levels rise, dopamine output increases, suppressing further prolactin release. This negative feedback loop maintains prolactin within normal ranges (typically 2-18 ng/mL in non-pregnant women and 2-18 ng/mL in men).
Cross-talk with growth hormone peptides. Arvat et al. (1997) demonstrated that GHRP-2 and hexarelin, two synthetic growth hormone-releasing peptides, stimulated not only GH but also prolactin, ACTH, and cortisol in healthy men. Prolactin responses to GHRP-2 peaked at 30 minutes and were dose-dependent, revealing that growth hormone secretagogue receptors on lactotroph cells provide an additional regulatory input.[3] Van den Berghe et al. (1999) confirmed this cross-talk in critically ill patients, showing that GHRP-2 infusion synchronized GH, TSH, and prolactin release, suggesting shared regulatory mechanisms among anterior pituitary hormones.[8]
Lactation: the primary function
Prolactin's most established role is in mammary gland development and milk production. During pregnancy, rising estrogen and progesterone stimulate lactotroph proliferation, increasing prolactin levels up to 10-fold. However, high progesterone levels block prolactin's action on the mammary gland. After delivery, the sharp decline in progesterone "unmasks" prolactin's lactogenic effect, initiating milk production.
The suckling reflex maintains lactation through a neuroendocrine arc: sensory stimulation from the nipple travels through the spinal cord to the hypothalamus, where it suppresses dopamine release and activates prolactin secretion. This mechanism works alongside oxytocin, which triggers the milk let-down reflex from a separate population of hypothalamic neurons. The two peptide hormones work in concert but through distinct pathways: prolactin drives milk synthesis, oxytocin drives milk ejection.
Prolactin levels during established breastfeeding follow a predictable pattern: baseline levels remain elevated (typically 40-200 ng/mL in the first months postpartum), with acute surges during each nursing session. The magnitude of these surges decreases over months of breastfeeding, even as milk production remains stable, because the mammary gland becomes increasingly sensitive to lower prolactin concentrations. In women who do not breastfeed, prolactin returns to baseline within 2-3 weeks postpartum.
The lactotroph cells that produce prolactin undergo massive expansion during pregnancy, increasing the size of the pituitary gland by up to 136%. This enlargement is driven primarily by estrogen-stimulated lactotroph hyperplasia and is the reason that pituitary MRI imaging must account for pregnancy status when assessing gland size. After weaning, lactotroph numbers regress through apoptosis, though not always completely, which may explain why some women retain slightly elevated prolactin levels after pregnancy.
Beyond the breast: prolactin's 300+ functions
The "300 functions" figure comes from cumulative research across vertebrate species. In humans, the most substantiated non-lactation functions include:
Immune regulation. Prolactin receptors are expressed on T cells, B cells, natural killer cells, and macrophages. Prolactin acts as a cytokine-like growth and differentiation factor for immune cells. Goya et al. (1999) demonstrated that the thymus-pituitary axis changes during aging, with declining prolactin contributing to age-related immunosenescence. The interplay between prolactin and thymic hormone production suggests prolactin helps maintain immune competence across the lifespan.[10]
Reproduction beyond lactation. In both sexes, prolactin modulates gonadal function. Excess prolactin suppresses GnRH pulsatile release from the hypothalamus, which in turn reduces FSH and LH secretion. This is why hyperprolactinemia causes menstrual irregularity in women and hypogonadism in men. Prolactin also plays a role in PCOS, where mildly elevated levels are found in some patients.
Metabolic functions. Prolactin receptors are present in adipose tissue, the liver, and pancreatic beta cells. During pregnancy, prolactin stimulates beta-cell proliferation and insulin secretion, a mechanism that helps meet the increased metabolic demands of gestation. This same mechanism may contribute to gestational diabetes when prolactin signaling is excessive or dysregulated.
Stress response modulation. Prolactin levels rise acutely in response to psychological and physical stress. Torner (2016) proposed that stress-induced prolactin has an anxiolytic function, dampening the hypothalamic-pituitary-adrenal axis response. This positions prolactin as a stress-buffering peptide, particularly in the postpartum period where elevated prolactin may reduce maternal anxiety during the vulnerable early parenting window.
Skin and hair. Prolactin receptors are expressed in keratinocytes, fibroblasts, sebaceous glands, and hair follicles. In the skin, prolactin acts as both a growth factor and an immune modulator. Hair follicles express prolactin and prolactin receptors locally, and in vitro studies have shown that prolactin promotes catagen (the regression phase of the hair cycle) in human scalp hair follicles. This finding has led to interest in prolactin receptor antagonists as potential treatments for hair loss, though no clinical applications have reached market.
Osmoregulation. Across vertebrate evolution, prolactin's most ancient function is water and electrolyte balance. In fish, prolactin is the primary freshwater-adaptation hormone. In humans, prolactin modulates renal sodium handling and may interact with vasopressin (ADH) signaling in the kidney, though this function is secondary to the more established actions of aldosterone and ADH.
Prolactin testing and clinical interpretation
A standard prolactin blood test (serum prolactin) is one of the most commonly ordered endocrine assays. Normal ranges vary by laboratory but generally fall between 2-29 ng/mL in non-pregnant women and 2-18 ng/mL in men. Levels above 250 ng/mL almost always indicate a prolactinoma; levels between 25-100 ng/mL have a broader differential including medications, stalk effect, and other causes.
Testing pitfalls include the "hook effect," where extremely high prolactin concentrations (typically above 10,000 ng/mL from large macroprolactinomas) saturate both the capture and detection antibodies in the immunoassay, producing falsely normal or low readings. If a large pituitary macroadenoma is present but prolactin appears normal, serial dilution of the sample will reveal the true level. Macroprolactinemia (prolactin bound to IgG) is another common source of false elevation, detectable through PEG precipitation.[2]
Timing of blood draw matters: prolactin levels peak during sleep (between 2-5 AM) and decline during waking hours. Stress from venipuncture itself can acutely elevate prolactin by 10-15 ng/mL. For borderline results, a rested, fasting morning sample drawn after the patient has been seated for at least 15-30 minutes provides the most accurate baseline.
Migraine. Singh et al. (2024) identified prolactin as a contributor to female-selective migraine mechanisms. Prolactin sensitizes trigeminal sensory neurons through prolactin receptors expressed on these pain-signaling cells, and cyclical fluctuations in prolactin levels may partly explain why migraines are three times more common in women than men.[9]
Hyperprolactinemia: when prolactin is too high
Hyperprolactinemia (prolactin above 25 ng/mL in women, above 20 ng/mL in men) is the most common hypothalamic-pituitary disorder. Causes fall into three categories:
Physiological. Pregnancy, lactation, sleep, stress, exercise, and nipple stimulation all elevate prolactin. These are normal and do not require treatment.
Pharmacological. Any medication that blocks dopamine or depletes dopamine stores can raise prolactin. This includes antipsychotics (risperidone is the most potent prolactin elevator), antiemetics (metoclopramide, domperidone), and some antidepressants. Liang et al. (2024) investigated this problem by conjugating the antipsychotic sulpiride with a cell-penetrating peptide, aiming to deliver the drug more selectively to the brain and reduce peripheral prolactin elevation. Their approach reduced serum prolactin compared to unconjugated sulpiride while maintaining antidepressant efficacy.[12]
Pathological. Prolactinomas (prolactin-secreting pituitary adenomas) are the most common functioning pituitary tumors, accounting for approximately 40% of all pituitary adenomas. Microprolactinomas (under 10 mm) are far more common than macroprolactinomas (over 10 mm). Prolactin levels often correlate with tumor size: microprolactinomas typically produce levels of 25-200 ng/mL, while macroprolactinomas can exceed 1,000 ng/mL.
Other pituitary tumors can cause hyperprolactinemia by compressing the pituitary stalk and blocking dopamine delivery (the "stalk effect"), typically producing levels below 100 ng/mL.
Treatment. Dopamine agonists (cabergoline, bromocriptine) are first-line therapy. They restore dopamine's inhibitory signal, shrinking prolactinomas by 50-80% in most patients and normalizing prolactin levels. Surgery (transsphenoidal adenomectomy) is reserved for dopamine agonist-resistant cases or when tumors cause acute visual compromise.
Agarwal et al. (2024) reported on peptide receptor radionuclide therapy (PRRT) for the rare case of prolactin-secreting pituitary carcinoma, an aggressive malignancy that does not respond to standard dopamine agonist therapy. Using radiolabeled somatostatin analog peptides that bind to somatostatin receptors on the tumor, PRRT represents an emerging peptide-based treatment for refractory prolactin-secreting tumors.[13]
Prolactin-releasing peptide: beyond prolactin
Prolactin-releasing peptide (PrRP) was named for its ability to stimulate prolactin secretion, but like prolactin itself, its functions extend far beyond its name. Takayanagi et al. (2008) demonstrated that PrRP-deficient mice developed late-onset obesity and increased food intake, establishing PrRP as an endogenous satiety signal. PrRP knockout mice showed increased adiposity, hyperphagia, and dysregulated glucose metabolism, particularly in older animals and those on high-fat diets.[5]
Li et al. (2024) resolved the crystal structure of PrRP bound to its receptor GPR10, revealing how the peptide's C-terminal amidated residues dock into the receptor's transmembrane bundle. This structural data opened the door to rational design of PrRP analogs with enhanced metabolic properties.[7]
Feetham et al. (2026) capitalized on this by developing a PrRP analog that reduced body weight in animal models primarily through sustained fatty acid oxidation rather than appetite suppression. This mechanism distinguishes it from GLP-1 agonists, which reduce weight primarily through appetite and gastric emptying effects. The PrRP analog maintained fat-burning effects over extended treatment periods without the nausea and gastrointestinal side effects common to incretin-based therapies.[11]
Prolactin and aging
The thymus-pituitary connection has implications for aging. Goya et al. (1999) described how the thymus-pituitary axis declines with age, with reduced prolactin-thymic hormone crosstalk contributing to immune senescence. The thymus, which produces T-cell maturation factors, is sensitive to prolactin signaling, and the age-related decline in both thymic function and prolactin may be mechanistically linked.[10]
Prolactin levels show sex-specific aging patterns. In women, prolactin declines after menopause alongside estrogen, which is a stimulator of lactotroph proliferation. In men, prolactin remains relatively stable but may rise with age-related increases in medication use (particularly proton pump inhibitors, opioids, and SSRIs). Dynorphin, an endogenous opioid peptide, modulates prolactin secretion through kappa opioid receptors, adding another layer to the opioid-prolactin-aging relationship (Youngren et al., 1993).[14]
Where prolactin research is heading
Three areas of active investigation stand out:
Metabolic therapy. The PrRP analog work by Feetham et al. (2026) suggests a new class of anti-obesity peptides that work through fat oxidation rather than appetite suppression. If this mechanism translates to humans, PrRP analogs could complement or compete with GLP-1 agonists in the obesity market.[11]
Targeted drug delivery. Liang et al. (2024) demonstrated that conjugating conventional drugs with cell-penetrating peptides could reduce prolactin-related side effects of antipsychotics. Given that antipsychotic-induced hyperprolactinemia affects up to 70% of patients on some medications, peptide-drug conjugates that maintain efficacy while sparing prolactin represent a clinically meaningful advance.[12]
Migraine biology. The identification of prolactin as a female-selective pain modulator opens questions about whether targeting prolactin receptors on trigeminal neurons could provide migraine relief beyond current CGRP-based therapies.[9]
Autoimmunity. Prolactin's immunostimulatory properties have a clinical downside. Hyperprolactinemia is associated with disease flares in systemic lupus erythematosus (SLE), and prolactin levels correlate with disease activity in some lupus cohorts. The mechanistic link involves prolactin's ability to promote B-cell survival and autoantibody production. Bromocriptine (a dopamine agonist that lowers prolactin) has been tested as adjunctive therapy in SLE, with some small trials showing reduced disease activity, though the evidence remains preliminary.
Cardiovascular risk. Epidemiological studies have linked both very high and very low prolactin levels to increased cardiovascular risk, following a U-shaped curve. Moderately elevated prolactin may be cardioprotective through endothelial prolactin receptor signaling, while extreme elevation (as in prolactinomas) is associated with metabolic syndrome, insulin resistance, and adverse lipid profiles. The 16 kDa prolactin fragment, which has anti-angiogenic properties, is implicated in peripartum cardiomyopathy and has become a therapeutic target: bromocriptine has been tested and approved in some European guidelines as a treatment for this condition, representing one of the few clinical applications of prolactin-lowering therapy outside of prolactinoma management.
Prolactin remains one of the most functionally diverse peptide hormones known. Its regulation sits at the intersection of dopamine, opioid, and releasing peptide signaling. Its effects span immunity, reproduction, metabolism, pain, and behavior. For a hormone named after milk, its reach extends to nearly every organ system in the body.
The Bottom Line
Prolactin is a 199-amino-acid peptide hormone produced primarily by pituitary lactotroph cells and regulated by tonic dopamine inhibition. While best known for driving lactation, prolactin participates in over 300 biological functions including immune modulation, metabolic regulation, stress response, and pain signaling. Current peptide research focuses on PrRP analogs for obesity treatment through fat oxidation, peptide-drug conjugates to reduce antipsychotic side effects, and prolactin's role in sex-selective migraine mechanisms.